ClinicalTrials.gov
public full text
Public Domain
NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D/CLDN18.2-based CAR-T cells infusion in the treatment of advanced NKG2DL+/CLDN18.2+ solid tumors.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors#914153
- NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors#877362
- Treatment of Malignant Tumors With NK Cell#888085
- NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors#314341
- Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia#1170926
Record · ID 810456
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive